KOKaren L. Osman

Karen L. Osman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Karen L. Osman has a total of 176 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Dissemination of OXA-23 carbapenemase-producing Proteus mirabilis and Escherichia coli is driven by transposon-carrying lineages in the UK

    by Roxana Zamudio, Karen Osman, Rachel Pike, Aiysha Chaudhry, Danièle Meunier, Nicole Stoesser, Rebecca Stretch, Jane F Turton, David Williams, Katie L. Hopkins

    Carbapenem-resistant Enterobacterales are a significant threat to global public health. Here, we characterize bla OXA-23-positive Proteus mirabilis (n=8) and Escherichia coli (n=3) isolates from human clinical samples collected between 2021 and 2024 in the UK. Whole-genome sequencing (WGS) was used to generate data, and a phylogenetic tree inferred from SNPs filtered for recombination was constructed to assess the genomic relatedness among the isolates. To provide an international context, we included publicly available genomes. Short-read mapping to a reference genome enabled reconstruction of the genomic neighbourhood around bla OXA-23. Minimum inhibitory concentration (MIC) determination was performed using broth microdilution and results interpreted using the European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines. UK P. mirabilis isolates belonged to ST142 and formed a sub-clade descending from an ancestral cluster of French isolates with relatively few SNPs between them (9–39). E. coli ST38 isolates harboured bla OXA-23 and showed close genetic relatedness (12–15 SNPs) among themselves. In P. mirabilis, bla OXA-23 was associated with transposon Tn6703, while E. coli harboured a novel composite transposon, designated Tn7816, bordered by two copies of IS26 and with three copies of bla OXA-23. bla OXA-23 was integrated into the chromosome in all isolates. All isolates were resistant to amoxicillin/clavulanic acid (>32 mg l−1) and with meropenem MICs above the EUCAST screening cut-off (0.5–1 mg l−1). In conclusion, UK bla OXA-23-positive P. mirabilis isolates belong to the same clonal lineage (ST142) previously reported in Belgium, Germany, Switzerland and France, suggesting introduction of this lineage into the UK. This is the first report of an E. coli ST38 lineage with chromosomally encoded bla OXA-23 located within a novel transposon Tn7816. WGS plays an important role in identifying the mechanism(s) of transmission of emerging carbapenemase genes.


  • Open Access

    Outbreak of Ralstonia pickettii associated with contamination of saline products distributed internationally, the United Kingdom, 2024

    by Mike Saunders, Amy Weaver, Rebecca Stretch, D Jeyaratnam, Mariyam Mirfenderesky, David Elliott, Charlotte Patterson, David Williams, Dervla Td Kenna, Karen L Osman, et al.

    We describe an outbreak of Ralstonia pickettii in the United Kingdom, with isolates genetically indistinguishable from a 2023 Australian outbreak linked to internationally distributed saline solutions. Confirmed cases (n = 3) had bacteraemia, clinically relevant infection, indwelling venous lines and frequent healthcare contact. Multi-stakeholder intervention was required including product recall and risk communications. We recommend a low threshold for investigating clusters of Ralstonia species and similar opportunistic pathogens, considering contaminated product sources. Effective mitigation requires multi-agency partnership and international collaboration.


  • Open Access

    Assessment of the Biological Impact of SARS-CoV-2 Genetic Variation Using an Authentic Virus Neutralisation Assay with Convalescent Plasma, Vaccinee Sera, and Standard Reagents

    by Naomi S. Coombes, Kevin R. Bewley, Yann Le Duff, Matthew Hurley, Lauren J. Smith, Thomas M. Weldon, Karen Osman, Steven Pullan, Neil Berry, Bassam Hallis, et al.

    In the summer of 2020, it became clear that the genetic composition of SARS-CoV-2 was changing rapidly. This was highlighted by the rapid emergence of the D614G mutation at that time. In the autumn of 2020, the project entitled “Agility” was initiated with funding from the Coalition for Epidemic Preparedness Innovations (CEPI) to assess new variants of SARS-CoV-2. The project was designed to reach out and intercept swabs containing live variant viruses in order to generate highly characterised master and working stocks, and to assess the biological consequences of the rapid genetic changes using both in vitro and in vivo approaches. Since November 2020, a total of 21 variants have been acquired and tested against either a panel of convalescent sera from early in the pandemic, and/or a panel of plasma from triple-vaccinated participants. A pattern of continuous evolution of SARS-CoV-2 has been revealed. Sequential characterisation of the most globally significant variants available to us, generated in real-time, indicated that the most recent Omicron variants appear to have evolved in a manner that avoids immunological recognition by convalescent plasma from the era of the ancestral virus when analysed in an authentic virus neutralisation assay.


  • Open Access

    Impact of bacterial strain acquisition in the lung of patients with COPD: the AERIS study

    by Lucio Malvisi, Aparna Yarraguntla, Marie-Cécile Mortier, Karen Osman, David W. Cleary, Béatrice Sente, Thierry G. Pascal, Vincent Weynants, Stuart C. Clarke, Laura Taddei, et al.

    Bacterial infections are associated with acute exacerbations of chronic obstructive pulmonary disease (AECOPD), but the mechanism is incompletely understood.In a COPD observational study (NCT013603...


  • Open Access

    The characterization of Moraxella catarrhalis carried in the general population

    by Denise E. Morris, Karen L. Osman, David W. Cleary, Stuart C. Clarke

    Moraxella catarrhalis is a common cause of respiratory tract infection, particularly otitis media in children, whilst it is also associated with the onset of exacerbation in chronic obstructive pulmonary disease in adults. Despite the need for an efficacious vaccine against M. catarrhalis , no candidates have progressed to clinical trial. This study, therefore, aimed to characterize the diversity of M. catarrhalis isolated from the upper respiratory tract of healthy children and adults, to gain a better understanding of the epidemiology of M. catarrhalis and the distribution of genes associated with virulence factors, to aid vaccine efforts. Isolates were sequenced and the presence of target genes reported. Contrary to prevailing data, this study found that lipooligosaccharide (LOS) B serotypes are not exclusively associated with 16S type 1. In addition, a particularly low prevalence of LOS B and high prevalence of LOS C serotypes was observed. M. catarrhalis isolates showed low prevalence of antimicrobial resistance and a high gene prevalence for a number of the target genes investigated: ompB2 (also known as copB), ompCD, ompE, ompG1a, ompG1b, mid (also known as hag), mcaP, m35, tbpA, lbpA, tbpB, lbpB, msp22, msp75 and msp78, afeA, pilA, pilQ, pilT, mod, oppA, sbp2, mcmA and mclS.


  • Open Access

    Convalescence from prototype SARS-CoV-2 protects Syrian hamsters from disease caused by the Omicron variant

    by Kathryn A. Ryan, Robert J. Watson, Kevin R. Bewley, Christopher Burton, Oliver Carnell, Breeze E. Cavell, Amy R Challis, Naomi S. Coombes, Kirsty Emery, Rachel Fell, et al.

    The mutation profile of the SARS-CoV-2 Omicron variant poses a concern for naturally acquired and vaccine-induced immunity. We investigated the ability of prior infection with an early SARS-CoV-2, 99.99% identical to Wuhan-Hu-1, to protect against disease caused by the Omicron variant. We established that infection with Omicron in naïve Syrian hamsters resulted in a less severe disease than a comparable dose of prototype SARS-CoV-2 (Australia/VIC01/2020), with fewer clinical signs and less weight loss. We present data to show that these clinical observations were almost absent in convalescent hamsters challenged with the same dose of Omicron 50 days after an initial infection with Australia/VIC01/2020. The data provide evidence for immunity raised against prototype SARS-CoV-2 being protective against Omicron in the Syrian hamster model. Further investigation is required to conclusively determine whether Omicron is less pathogenic in Syrian hamsters and whether this is predictive of pathogenicity in humans.


  • Open Access

    A cautionary perspective regarding the isolation and serial propagation of SARS-CoV-2 in Vero cells

    by Simon G. P. Funnell, Babak Afrough, John James Baczenas, Neil Berry, Kevin R. Bewley, Rebecca Bradford, Clint Florence, Yann Le Duff, Mark Lewis, Ryan V. Moriarty, et al.

    An array of SARS-CoV-2 virus variants have been isolated, propagated and used in in vitro assays, in vivo animal studies and human clinical trials. Observations of working stocks of SARS-CoV-2 suggest that sequential propagation in Vero cells leads to critical changes in the region of the furin cleavage site, which significantly reduce the value of the working stock for critical research studies. Serially propagating SARS-CoV-2 in Vero E6 cells leads to rapid increases in genetic variants while propagation in other cell lines (e.g. Vero/hSLAM) appears to mitigate this risk thereby improving the overall genetic stability of working stocks. From these observations, investigators are urged to monitor genetic variants carefully when propagating SARS-CoV-2 in Vero cells.


  • Open Access

    Dose-dependent response to infection with SARS-CoV-2 in the ferret model and evidence of protective immunity

    by Kathryn A. Ryan, Kevin R. Bewley, Susan A. Fotheringham, Gillian S. Slack, Phillip Brown, Yper Hall, Nadina I. Wand, Anthony C. Marriott, Breeze E. Cavell, Julia A. Tree, et al.

    There is a vital need for authentic COVID-19 animal models to enable the pre-clinical evaluation of candidate vaccines and therapeutics. Here we report a dose titration study of SARS-CoV-2 in the ferret model. After a high (5 × 106 pfu) and medium (5 × 104 pfu) dose of virus is delivered, intranasally, viral RNA shedding in the upper respiratory tract (URT) is observed in 6/6 animals, however, only 1/6 ferrets show similar signs after low dose (5 × 102 pfu) challenge. Following sequential culls pathological signs of mild multifocal bronchopneumonia in approximately 5–15% of the lung is seen on day 3, in high and medium dosed groups. Ferrets re-challenged, after virus shedding ceased, are fully protected from acute lung pathology. The endpoints of URT viral RNA replication & distinct lung pathology are observed most consistently in the high dose group. This ferret model of SARS-CoV-2 infection presents a mild clinical disease.


  • Open Access

    Patients with Chronic Obstructive Pulmonary Disease harbour a variation of Haemophilus species

    by Karen L Osman, Johanna M C Jefferies, Christopher H Woelk, Nathalie Devos, Thierry G Pascal, Marie-Cécile Mortier, Jeanne-Marie Devaster, Tom M A Wilkinson, David W Cleary, Stuart C Clarke, et al.

    H. haemolyticus is often misidentified as NTHi due to their close phylogenetic relationship. Differentiating between the two is important for correct identification and appropriate treatment of infective organism and to ensure any role of H. haemolyticus in disease is not being overlooked. Speciation however is not completely reliable by culture and PCR methods due to the loss of haemolysis by H. haemolyticus and the heterogeneity of NTHi. Haemophilus isolates from COPD as part of the AERIS study (ClinicalTrials - NCT01360398) were speciated by analysing sequence data for the presence of molecular markers. Further investigation into the genomic relationship was carried out using average nucleotide identity and phylogeny of allelic and genome alignments. Only 6.3% were identified as H. haemolyticus. Multiple in silico methods were able to distinguish H. haemolyticus from NTHi. However, no single gene target was found to be 100% accurate. A group of omp2 negative NTHi were observed to be phylogenetically divergent from H. haemolyticus and remaining NTHi. The presence of an atypical group from a geographically and disease limited set of isolates supports the theory that the heterogeneity of NTHi may provide a genetic continuum between NTHi and H. haemolyticus.


  • Open Access

    Pneumococcal vaccine impacts on the population genomics of non-typeable Haemophilus influenzae

    by David Cleary, Vanessa Devine, Denise Morris, Karen Osman, Rebecca Gladstone, Stephen Bentley, Saul Faust, Stuart Clarke

    The implementation of pneumococcal conjugate vaccines (PCVs) has led to a decline in vaccine-type disease. However, there is evidence that the epidemiology of non-typeable Haemophilus influenzae (NTHi) carriage and disease can be altered as a consequence of PCV introduction. We explored the epidemiological shifts in NTHi carriage using whole genome sequencing over a 5-year period that included PCV13 replacement of PCV7 in the UK’s National Immunization Programme in 2010. Between 2008/09 and 2012/13 (October to March), nasopharyngeal swabs were taken from children <5 years of age. Significantly increased carriage post-PCV13 was observed and lineage-specific associations with Streptococcus pneumoniae were seen before but not after PCV13 introduction. NTHi were characterized into 11 discrete, temporally stable lineages, congruent with current knowledge regarding the clonality of NTHi. The increased carriage could not be linked to the expansion of a particular clone and different co-carriage dynamics were seen before PCV13 implementation when NTHi co-carried with vaccine serotype pneumococci. In summary, PCV13 introduction has been shown to have an indirect effect on NTHi epidemiology and there exists both negative and positive, distinct associations between pneumococci and NTHi. This should be considered when evaluating the impacts of pneumococcal vaccine design and policy.